The Future of Paediatric Heart Interventions: Where Will We Be in 2030?
- PDF / 647,134 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 108 Downloads / 213 Views
CONGENITAL HEART DISEASE (RA KRASUSKI AND G FLEMING, SECTION EDITORS)
The Future of Paediatric Heart Interventions: Where Will We Be in 2030? Tomohito Kogure 1,2 & Shakeel A. Qureshi 1 Accepted: 1 September 2020 # The Author(s) 2020
Abstract Purpose of Review Cardiac catheterization therapies to treat or palliate infants, children and adults with congenital heart disease have developed rapidly worldwide in both technical innovation and device development in the previous three decades. By reviewing of current status of novel or development of devices and techniques, we will discuss what is likely to happen in paediatric heart intervention in the next decade. Recent Findings Recently, biodegradable stents and devices, transcatheter pulmonary valve implantation for the native right ventricle outflow tract and MRI-guided interventions have been progressing rapidly with good immediate to early results. These are expected to be introduced and spread in the next decade although there are still challenges to overcome. Summary The future of paediatric heart intervention is very promising with rapid development of technological progress. Keywords Congenital heart disease . Cardiac catheterization . Biodegradable devices . Percutaneous pulmonary valve implantation . MRI-guided interventions
Introduction Cardiac catheterization therapies for infants, children and adults with congenital heart disease (CHD) have progressed rapidly worldwide since Dr. William Rashkind reported the first balloon atrial septostomy for transposition of the great arteries in 1966 [1]. This was followed by the development of balloon valvoplasties and angioplasties in the 1980s [2, 3]. Stent implantation and coil embolization were developed in the 1990s [4, 5], and device closure of septal defect and patent ductus arteriosus became popular throughout the world in the 1990s and 2000s [6–9], as well as development of imaging technology [10, 11]. Nowadays, hybrid interventions [9, 12] This article is part of the Topical Collection on Congenital Heart Disease * Shakeel A. Qureshi [email protected] Tomohito Kogure [email protected] 1
Department of Congenital Cardiology, Evelina London Children’s Hospital, Guy’s and St Thomas’ NHS Foundation Trust, London SE1 7EH, UK
2
Department of Cardiology, Tokyo Women’s Medical University, Tokyo 162-0054, Japan
and percutaneous pulmonary valve implantation are performed, supported by three-dimensional echocardiography or CT or MRI. Catheter intervention has become wellestablished, and the therapeutic range of interventions continues to expand with development of newer devices and techniques. In this article, we will describe the current status and future expectation of biodegradable stents and devices, transcatheter pulmonary valve implantation for the native right ventricle outflow tract and MRI-guided interventions as these are expected to become widespread in the next decade.
Biodegradable Stents and Devices Biodegradable Stents For congenital heart disease, biodegradable stents will likel
Data Loading...
